{
  "$schema": "folio-library-document/v1",
  "id": "10665-325892",
  "title": "Policy brief: update of recommendations on first- and second-line antiretroviral regimens",
  "variant": "pdf",
  "pages": 16,
  "tocSource": "inferred",
  "tocMethod": "font",
  "toc": [
    {
      "level": 1,
      "title": "WHO/CDS/HIV/19.15",
      "number": null,
      "page": 2,
      "pageLabel": null,
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-whocdshiv1915"
    },
    {
      "level": 2,
      "title": "© World Health Organization 2019",
      "number": null,
      "page": 2,
      "pageLabel": null,
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-world-health-organization-2019"
    },
    {
      "level": 1,
      "title": "BACKGROUND",
      "number": null,
      "page": 3,
      "pageLabel": "3",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-background"
    },
    {
      "level": 1,
      "title": "DTG IN FIRST-LINE ART",
      "number": null,
      "page": 4,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-dtg-in-first-line-art"
    },
    {
      "level": 2,
      "title": "to women exposed to DTG before conception or early in pregnancy",
      "number": null,
      "page": 4,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-to-women-exposed-to-dtg-before-conception-or-ear"
    },
    {
      "level": 2,
      "title": "\u0007Box 3: A woman-centred approach",
      "number": null,
      "page": 5,
      "pageLabel": "5",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-box-3-a-woman-centred-approach"
    },
    {
      "level": 2,
      "title": "EFV 400 mg in first-line ART",
      "number": null,
      "page": 6,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-006-efv-400-mg-in-first-line-art"
    },
    {
      "level": 2,
      "title": "DTG in second-line ART",
      "number": null,
      "page": 8,
      "pageLabel": "8",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-007-dtg-in-second-line-art"
    },
    {
      "level": 2,
      "title": "Transition to DTG and EFV 400 mg in national HIV programmes",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-008-transition-to-dtg-and-efv-400-mg-in-national-hiv"
    },
    {
      "level": 2,
      "title": "Clinical and implementation considerations",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-009-clinical-and-implementation-considerations"
    },
    {
      "level": 2,
      "title": "considered stable on ART based on national guidelines",
      "number": null,
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-considered-stable-on-art-based-on-national-guide"
    },
    {
      "level": 3,
      "title": "AZT + 3TC + NVP",
      "number": null,
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-azt-3tc-nvp"
    },
    {
      "level": 3,
      "title": "AZT + 3TC + EFV",
      "number": null,
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-azt-3tc-efv"
    },
    {
      "level": 3,
      "title": "ABC + 3TC + NVP",
      "number": null,
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-abc-3tc-nvp"
    },
    {
      "level": 3,
      "title": "ABC + 3TC + EFV",
      "number": null,
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-abc-3tc-efv"
    },
    {
      "level": 1,
      "title": "REFERENCES",
      "number": null,
      "page": 14,
      "pageLabel": "14",
      "confidence": 0.7,
      "evidence": [
        "style",
        "stock-name"
      ],
      "source": "inferred",
      "section": "sec-015-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": null,
      "words": 15,
      "summary": {
        "text": "The cover of the July 2019 WHO HIV treatment policy brief on updated recommendations for first- and second-line antiretroviral regimens.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS JULY 2019 POLICY BRIEF HIV TREATMENT",
      "extractCut": false,
      "blocks": [
        "library/10665-325892/blocks/prose-sec-front-matter",
        "library/10665-325892/blocks/figure-img-p001-1"
      ]
    },
    {
      "id": "sec-000-whocdshiv1915",
      "number": null,
      "title": "WHO/CDS/HIV/19.15",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": null,
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-001-world-health-organization-2019",
      "number": null,
      "title": "© World Health Organization 2019",
      "level": 2,
      "pageStart": 2,
      "pageEnd": 3,
      "labelStart": null,
      "labelEnd": "3",
      "words": 479,
      "summary": {
        "text": "The copyright and licensing page of the 2019 policy brief, setting out Creative Commons BY-NC-SA 3.0 IGO terms, citation and translation conditions, and standard WHO disclaimers. It also credits the cover photo and layout and notes printing in Switzerland.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health organization",
          "heading": true
        },
        {
          "term": "world health",
          "heading": true
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "igo",
          "heading": false
        },
        {
          "term": "by-nc-sa",
          "heading": false
        },
        {
          "term": "work",
          "heading": false
        }
      ],
      "extract": "Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no",
      "extractCut": true
    },
    {
      "id": "sec-002-background",
      "number": null,
      "title": "BACKGROUND",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 4,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 491,
      "summary": {
        "text": "Explains the background to the 2019 update: the 2018 interim guidance preferring dolutegravir (DTG) regimens, caution over a neural tube defect signal in Botswana, and gaps in evidence on efavirenz 400 mg. It then sets out the updated recommendations in a box, naming DTG-based regimens as preferred first- and second-line therapy, efavirenz 400 mg and raltegravir as alternatives, with strength and certainty ratings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dtg dosing",
          "heading": false
        },
        {
          "term": "approved dtg",
          "heading": false
        },
        {
          "term": "second-line regimen",
          "heading": false
        },
        {
          "term": "first-line regimen",
          "heading": false
        },
        {
          "term": "nrti backbone",
          "heading": false
        },
        {
          "term": "preferred second-line",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "second-line art",
          "heading": false
        }
      ],
      "extract": "In 2018, WHO published interim guidelines recommending dolutegravir (DTG)-containing regimens as the preferred first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (1). However, a note of caution about women of childbearing potential using DTG was issued following a signal of a potential association of neural tube defects and women’s use of DTG at the time of conception in an",
      "extractCut": true
    },
    {
      "id": "sec-003-dtg-in-first-line-art",
      "number": null,
      "title": "DTG IN FIRST-LINE ART",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 253,
      "summary": {
        "text": "Summarizes the 2019 systematic review showing DTG-based first-line therapy outperforms efavirenz on viral suppression, discontinuation and resistance, with fewer drug interactions and activity against HIV-2. It notes risks of sleep problems and weight gain and says women should receive information on benefits and risks of DTG at conception to make informed choices.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dtg",
          "heading": true
        },
        {
          "term": "neural tube",
          "heading": false
        },
        {
          "term": "tube defects",
          "heading": false
        },
        {
          "term": "viral suppression",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "hiv drug",
          "heading": false
        },
        {
          "term": "efv",
          "heading": false
        },
        {
          "term": "first-line",
          "heading": true
        }
      ],
      "extract": "An updated systematic review conducted in 2019 to support the guidelines reaffirmed that a first-line regimen of DTG combined with two nucleoside reverse-transcriptase inhibitors (NRTIs) leads to higher viral suppression and lower risk of discontinuing treatment and developing HIV drug resistance compared with EFV-based regimens among treatment- naive adults. DTG has other advantages over EFV, including lower",
      "extractCut": true
    },
    {
      "id": "sec-004-to-women-exposed-to-dtg-before-conception-or-ear",
      "number": null,
      "title": "to women exposed to DTG before conception or early in pregnancy",
      "level": 2,
      "pageStart": 4,
      "pageEnd": 5,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 454,
      "summary": {
        "text": "Updates the evidence on neural tube defects among infants born to women taking DTG at conception, reporting a fall in the Tsepamo study estimate to 0.30% and additional surveillance data from Botswana. It places the absolute risk as very low, notes the role of folate fortification and calls for continued surveillance, and concludes that modelling favours DTG on balance and cost-effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "neural tube",
          "heading": false
        },
        {
          "term": "tube defect",
          "heading": false
        },
        {
          "term": "dtg",
          "heading": true
        },
        {
          "term": "periconception exposures",
          "heading": false
        },
        {
          "term": "folate fortification",
          "heading": false
        },
        {
          "term": "defect signal",
          "heading": false
        },
        {
          "term": "conception",
          "heading": true
        },
        {
          "term": "dtg art",
          "heading": false
        }
      ],
      "extract": "Although the prevalence of neural tube defects associated with using DTG at conception in the Tsepamo study has declined from 0.94% (4 of 426 exposures) to 0.30% (5 of 1683 exposures), the prevalence difference remains statistically significantly higher than all other ARV drug exposure groups. A further study by the Botswana Ministry of Health and the United States Centers for Disease Control and Prevention (CDC)",
      "extractCut": true
    },
    {
      "id": "sec-005-box-3-a-woman-centred-approach",
      "number": null,
      "title": "\u0007Box 3: A woman-centred approach",
      "level": 2,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 387,
      "summary": {
        "text": "Describes a woman-centred, human rights-based approach to antiretroviral therapy that respects women's autonomy and informed choice. It then covers DTG approval and formulations for children, raltegravir as an option from birth, and the need for twice-daily DTG in people with HIV and TB on rifampicin.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "woman-centred",
          "heading": true
        },
        {
          "term": "children weighing",
          "heading": false
        },
        {
          "term": "rights-based approach",
          "heading": false
        },
        {
          "term": "dtg",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "human rights-based",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        }
      ],
      "extract": "Woman-centred health services involve an approach to health care that consciously adopts the perspectives of women and their families and communities. This means that health services see women as active participants in and beneficiaries of trusted health systems that respond to women’s needs, rights and preferences in humane and holistic ways (with no coercion). Care is provided in ways that respect a woman’s",
      "extractCut": true
    },
    {
      "id": "sec-006-efv-400-mg-in-first-line-art",
      "number": null,
      "title": "EFV 400 mg in first-line ART",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "6",
      "labelEnd": "8",
      "words": 947,
      "summary": {
        "text": "Reviews evidence showing efavirenz 400 mg is better tolerated than the 600 mg dose, with similar viral suppression, lower cost and expected safety in pregnancy. It discusses limited data on its use with rifampicin-based TB treatment and its pharmacokinetics in pregnancy. It then introduces the review of DTG for people whose non-DTG first-line regimen has failed, finding DTG generally outperforms protease-inhibitor-based second-line therapy on safety and efficacy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "efv",
          "heading": true
        },
        {
          "term": "efv mgb",
          "heading": false
        },
        {
          "term": "lpv solid",
          "heading": false
        },
        {
          "term": "weight gain",
          "heading": false
        },
        {
          "term": "first-line regimen",
          "heading": false
        },
        {
          "term": "art regimens",
          "heading": false
        },
        {
          "term": "potential weight",
          "heading": false
        },
        {
          "term": "dtg",
          "heading": false
        }
      ],
      "extract": "The updated systematic review found that EFV 400 mg is better tolerated than EFV in standard dose (EFV 600 mg), with lower risk of treatment discontinuation and severe treatment- related adverse events. Regimens containing EFV 400 mg and EFV 600 mg were comparable for viral suppression, mortality and mental and nervous system adverse events. EFV 400 mg is available in a smaller pill size and can potentially reduce",
      "extractCut": true
    },
    {
      "id": "sec-007-dtg-in-second-line-art",
      "number": null,
      "title": "DTG in second-line ART",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 589,
      "summary": {
        "text": "Recommends DTG as the preferred second-line drug for adults, adolescents and children failing non-DTG first-line regimens, and a boosted protease inhibitor for those failing DTG-based first-line therapy. Table 2 lists preferred and alternative second-line regimens by population and failing regimen, with footnotes on dosing and use in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "second-line art",
          "heading": true
        },
        {
          "term": "dtg",
          "heading": true
        },
        {
          "term": "atv",
          "heading": false
        },
        {
          "term": "first-line regimen",
          "heading": false
        },
        {
          "term": "drv",
          "heading": false
        },
        {
          "term": "alternative second-line",
          "heading": false
        },
        {
          "term": "lpv",
          "heading": false
        },
        {
          "term": "azt",
          "heading": false
        }
      ],
      "extract": "Taken together with other advantages, including lower cost, less potential for drug–drug interactions, lower pill burden and availability in once-daily fixed-dose combinations, DTG is recommended as the preferred ARV drug for second-line ART among adults, adolescents and children for whom a non-DTG-based first-line regimen has failed. For those taking a first-line regimen containing DTG that has failed, a boosted",
      "extractCut": true
    },
    {
      "id": "sec-008-transition-to-dtg-and-efv-400-mg-in-national-hiv",
      "number": null,
      "title": "Transition to DTG and EFV 400 mg in national HIV programmes",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 3,
      "summary": {
        "text": "A section heading fragment on transitioning national HIV programmes to DTG and efavirenz 400 mg.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "national HIV programmes",
      "extractCut": false
    },
    {
      "id": "sec-009-clinical-and-implementation-considerations",
      "number": null,
      "title": "Clinical and implementation considerations",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 12,
      "labelStart": "9",
      "labelEnd": "12",
      "words": 1167,
      "summary": {
        "text": "Describes manufacturing capacity for DTG and progress by countries in adopting efavirenz 400 mg and DTG into guidelines and procurement. It sets out drug–drug interaction cautions, such as with certain anticonvulsants and cation-containing antacids and supplements, and advises a phased transition with buffer stocks. Tables summarize considerations for transitioning adults, adolescents and children who are stable on ART to optimal regimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dtg among",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "initiate tdf",
          "heading": false
        },
        {
          "term": "art regimens",
          "heading": false
        },
        {
          "term": "optimal regimens",
          "heading": false
        },
        {
          "term": "optimal formulations",
          "heading": false
        },
        {
          "term": "first-line art",
          "heading": false
        },
        {
          "term": "load testing",
          "heading": false
        }
      ],
      "extract": "considerations Multiple suppliers are capable of manufacturing DTG as a single product and as part of a fixed-dose combination and have already begun expanding capacity to cope with the increased demand. No shortfalls in manufacturing capacity are currently anticipated, although countries should undertake effective supply planning. Kenya, Zambia and Zimbabwe have transitioned from EFV 600 mg to EFV 400 mg, and about",
      "extractCut": true
    },
    {
      "id": "sec-010-considered-stable-on-art-based-on-national-guide",
      "number": null,
      "title": "considered stable on ART based on national guidelines",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 8,
      "summary": {
        "text": "Column headings of a table on transitioning children considered stable on ART: current regimen, weight, optimal regimen and considerations.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Current regimen Weight Optimal regimen for transition Considerations",
      "extractCut": false
    },
    {
      "id": "sec-011-azt-3tc-nvp",
      "number": null,
      "title": "AZT + 3TC + NVP",
      "level": 3,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-012-azt-3tc-efv",
      "number": null,
      "title": "AZT + 3TC + EFV",
      "level": 3,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-013-abc-3tc-nvp",
      "number": null,
      "title": "ABC + 3TC + NVP",
      "level": 3,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 52,
      "summary": {
        "text": "Table rows giving weight-based transition options for children currently on abacavir, lamivudine and nevirapine, moving to DTG-based regimens as they reach 20 kg and 30 kg.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "<20 kg ABC + 3TC + LPV/r If stable, children can be transitioned to DTG when they reach 20 kg 20–30kg ABC + 3TC + DTG If stable, children can be transitioned to TDF + 3TC + DTG when they reach 30 kg > 30 kg TDF + 3TC + DTG –",
      "extractCut": false
    },
    {
      "id": "sec-014-abc-3tc-efv",
      "number": null,
      "title": "ABC + 3TC + EFV",
      "level": 3,
      "pageStart": 12,
      "pageEnd": 14,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 576,
      "summary": {
        "text": "Continues the transition table for children on efavirenz- or lopinavir/ritonavir-based regimens, giving weight-banded options and advice on reducing pill burden. It is followed by the opening references of the policy brief, on DTG, efavirenz and the transition to new antiretrovirals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "abc",
          "heading": true
        },
        {
          "term": "dolutegravir",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "dtg",
          "heading": false
        },
        {
          "term": "antiretroviral drugs",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "lpv",
          "heading": false
        }
      ],
      "extract": "<20 kg No change until they reach 20 kg unless treatment failure occurs Transition to optimal regimens for these children is of value once they reach 20 kg and DTG can be used maintaining once-daily administration 20–30 kg ABC + 3TC + DTG If stable, children can be transitioned to TDF + 3TC + DTG when they reach 30 kg > 30 kg TDF + 3TC + DTG – ABC + 3TC + LPV/r AZT + 3TC + LPV/r <20 kg No change until they reach 20",
      "extractCut": true
    },
    {
      "id": "sec-015-references",
      "number": null,
      "title": "REFERENCES",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 16,
      "labelStart": "14",
      "labelEnd": null,
      "words": 368,
      "summary": {
        "text": "The remainder of the reference list for the 2019 antiretroviral policy brief, citing studies on weight gain, DTG risk–benefit modelling and spina bifida prevalence, followed by WHO HIV/AIDS department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "handle who-cds-hiv",
          "heading": false
        },
        {
          "term": "dolutegravir-based antiretroviral",
          "heading": false
        },
        {
          "term": "formulary",
          "heading": false
        },
        {
          "term": "pozniak",
          "heading": false
        },
        {
          "term": "accessed",
          "heading": false
        },
        {
          "term": "dooley",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "13. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5:e45–7. 14. Dugdale CM, Ciaranello AL, Bekker L-G, Stern ME, Myer L, Wood R et al. Risks and benefits of dolutegravir-and efavirenz-based strategies for South African women with HIV of child-bearing potential: a modeling study. Ann Intern Med. 2019;170:614–25. 15. Phillips AN, Venter F,",
      "extractCut": true
    }
  ],
  "checks": {
    "figureSequenceGaps": [
      "box 3"
    ],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "dtg art",
      "heading": true
    },
    {
      "term": "dtg dosing",
      "heading": false
    },
    {
      "term": "dtg among",
      "heading": true
    },
    {
      "term": "approved dtg",
      "heading": false
    },
    {
      "term": "neural tube",
      "heading": true
    },
    {
      "term": "art regimens",
      "heading": true
    },
    {
      "term": "efv mgb",
      "heading": false
    },
    {
      "term": "tube defects",
      "heading": true
    },
    {
      "term": "first-line art",
      "heading": true
    },
    {
      "term": "second-line regimens",
      "heading": true
    },
    {
      "term": "childbearing potential",
      "heading": false
    },
    {
      "term": "antiretroviral regimens",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 3,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 12,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": null,
      "source": null,
      "confidence": 0
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "Recommendations: firstand second-line ART regimens",
      "page": 3,
      "pageLabel": "3",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "Updates on the risk of neural tube defects among infants born",
      "page": 4,
      "pageLabel": "4",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4",
      "title": "Weight Gain and new ARV use",
      "page": 6,
      "pageLabel": "6",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Preferred and alternative first-line ART regimens",
      "page": 7,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Preferred and alternative second-line ART regimens",
      "page": 8,
      "pageLabel": "8",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "1",
      "title": "Major factors that can influence the transition to DTG",
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Considerations for transition to TDF + 3TC + DTG among adults and adolescents",
      "page": 11,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "Considerations for transition to optimal ART regimens for children who are",
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "A photograph of a man in a blue T-shirt standing in a home and looking down at two small white medicine bottles in his hands. Behind him are floral and turquoise curtains and a television on a table covered with a red cloth.",
        "ar": "صورة فوتوغرافية لرجل يرتدي قميصاً أزرق يقف في منزل وينظر إلى قارورتي دواء بيضاوين صغيرتين في يديه. وخلفه ستائر مزهّرة وفيروزية وجهاز تلفاز على طاولة مغطاة بقماش أحمر.",
        "zh": "一张照片：一名身穿蓝色T恤的男子站在家中，低头看着手中两个白色小药瓶。他身后是花卉图案和青绿色的窗帘，以及放在铺着红布的桌子上的一台电视机。",
        "es": "Fotografía de un hombre con camiseta azul de pie en una vivienda, mirando dos pequeños frascos blancos de medicamentos que sostiene en las manos. Detrás hay cortinas floreadas y turquesas y un televisor sobre una mesa cubierta con un paño rojo.",
        "fr": "Photographie d’un homme en t-shirt bleu, debout dans un logement, regardant deux petits flacons blancs de médicaments qu’il tient dans les mains. Derrière lui, des rideaux fleuris et turquoise et un téléviseur posé sur une table recouverte d’un tissu rouge.",
        "ru": "Фотография мужчины в голубой футболке, который стоит в доме и смотрит на два небольших белых флакона с лекарствами в руках. За ним — занавески с цветочным узором и бирюзовые шторы, а также телевизор на столе, покрытом красной тканью."
      },
      "state": "draft"
    },
    {
      "id": "img-p005-1",
      "file": "images/img-p005-1.webp",
      "page": 5,
      "narratives": {
        "en": "A photograph of a smiling older woman in a brown hat and purple cardigan carrying a large bundle of green stalks with yellow flowers on her back, tied with a striped cloth across her chest.",
        "ar": "صورة فوتوغرافية لامرأة مسنّة مبتسمة ترتدي قبعة بنية وسترة بنفسجية، تحمل على ظهرها حزمة كبيرة من السيقان الخضراء ذات الأزهار الصفراء، مربوطة بقطعة قماش مخططة على صدرها.",
        "zh": "一张照片：一位面带微笑的年长妇女头戴棕色帽子、身穿紫色开衫，背上背着一大捆开着黄花的绿色茎秆，用一块条纹布系在胸前。",
        "es": "Fotografía de una mujer mayor sonriente, con sombrero marrón y chaqueta morada, que carga a la espalda un gran haz de tallos verdes con flores amarillas, atado con un paño a rayas sobre el pecho.",
        "fr": "Photographie d’une femme âgée souriante, coiffée d’un chapeau marron et vêtue d’un gilet violet, portant sur le dos une grosse botte de tiges vertes à fleurs jaunes, attachée par un tissu rayé sur la poitrine.",
        "ru": "Фотография улыбающейся пожилой женщины в коричневой шляпе и фиолетовой кофте, которая несёт на спине большую охапку зелёных стеблей с жёлтыми цветами, перевязанную на груди полосатой тканью."
      },
      "state": "draft"
    },
    {
      "id": "img-p007-1",
      "file": "images/img-p007-1.webp",
      "page": 7,
      "narratives": {
        "en": "A photograph of a smiling woman, a man and a small child standing on a white backdrop outside a house. The woman holds a sign reading “AIDS treatment for all” and the man a sign reading “Acceptance of all HIV+ people”.",
        "ar": "صورة فوتوغرافية لامرأة مبتسمة ورجل وطفل صغير يقفون على خلفية بيضاء خارج منزل. تحمل المرأة لافتة كُتب عليها «علاج الإيدز للجميع»، ويحمل الرجل لافتة كُتب عليها «قبول جميع المصابين بفيروس العوز المناعي البشري».",
        "zh": "一张照片：一名微笑的女子、一名男子和一个小孩站在房屋外的白色背景布上。女子举着写有“艾滋病治疗惠及所有人”的牌子，男子举着写有“接纳所有艾滋病毒阳性者”的牌子。",
        "es": "Fotografía de una mujer sonriente, un hombre y un niño pequeño de pie sobre un fondo blanco fuera de una casa. La mujer sostiene un cartel que dice «Tratamiento del sida para todos» y el hombre otro que dice «Aceptación de todas las personas VIH+».",
        "fr": "Photographie d’une femme souriante, d’un homme et d’un jeune enfant debout sur un fond blanc devant une maison. La femme tient une pancarte indiquant « Traitement du sida pour tous » et l’homme une pancarte indiquant « Acceptation de toutes les personnes VIH+ ».",
        "ru": "Фотография улыбающейся женщины, мужчины и маленького ребёнка на белом фоне перед домом. Женщина держит табличку «Лечение СПИДа для всех», мужчина — табличку «Принятие всех ВИЧ-положительных людей»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p009",
      "file": "figures/vfig-p009.webp",
      "page": 9,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "A page render with two columns of text above Figure 1, “Major factors that can influence the transition to DTG”, a three-column diagram with icons. Clinical and epidemiological factors include the percentage of women with HIV of childbearing potential, use of suboptimal first-line regimens, availability of second- and third-line options and pre-treatment NNRTI resistance. Commodities include stocks of EFV and DTG, access to contraception and viral load testing, and availability of fixed-dose and generic formulations. Programme and policy factors include inclusion in national guidelines, supply chain capacity, training of health-care providers, translating the policy to community, and toxicity and pregnancy safety monitoring.",
        "ar": "صورة لصفحة تضم عمودين من النص فوق الشكل 1 «العوامل الرئيسية التي يمكن أن تؤثر في الانتقال إلى الدولوتيغرافير (DTG)»، وهو مخطط من ثلاثة أعمدة مع أيقونات. تشمل العوامل السريرية والوبائية نسبة النساء المصابات بفيروس العوز المناعي البشري في سن الإنجاب، واستخدام نُظم خط أول دون المستوى الأمثل، وتوافر خيارات الخطين الثاني والثالث، ومقاومة مثبطات المنتسخة العكسية غير النوكليوزيدية قبل العلاج. وتشمل السلع مخزونات الإيفافيرنز والدولوتيغرافير، وإتاحة وسائل منع الحمل واختبار الحمل الفيروسي، وتوافر التركيبات ثابتة الجرعات والتركيبات الجنيسة. وتشمل عوامل البرامج والسياسات الإدراج في المبادئ التوجيهية الوطنية، وقدرة سلسلة الإمداد، وتدريب مقدّمي الرعاية الصحية، وترجمة السياسة إلى المجتمع المحلي، ورصد السمّية والمأمونية في الحمل.",
        "zh": "页面渲染图，上方为两栏文字，下方为图1“可能影响向多替拉韦（DTG）过渡的主要因素”，这是一张带图标的三栏示意图。临床和流行病学因素包括育龄期感染艾滋病毒妇女的比例、使用次优一线方案、二线和三线方案的可得性以及治疗前对非核苷类逆转录酶抑制剂的耐药。商品因素包括依非韦伦和多替拉韦的库存、获得避孕和病毒载量检测的机会，以及固定剂量复方制剂和仿制药的可得性。规划和政策因素包括纳入国家指南、供应链能力、卫生保健提供者培训、将政策传达到社区，以及毒性监测和妊娠安全性监测。",
        "es": "Imagen de una página con dos columnas de texto sobre la Figura 1, «Principales factores que pueden influir en la transición al DTG», un diagrama de tres columnas con iconos. Los factores clínicos y epidemiológicos incluyen el porcentaje de mujeres con VIH en edad fecunda, el uso de pautas de primera línea subóptimas, la disponibilidad de opciones de segunda y tercera línea y la resistencia pretratamiento a los INNTI. Los productos incluyen las existencias de EFV y DTG, el acceso a la anticoncepción y a las pruebas de carga viral y la disponibilidad de formulaciones de dosis fijas y genéricas. Los factores de programa y política incluyen la inclusión en las directrices nacionales, la capacidad de la cadena de suministro, la formación del personal de salud, la traslación de la política a la comunidad y el seguimiento de la toxicidad y de la seguridad en el embarazo.",
        "fr": "Rendu d’une page avec deux colonnes de texte au-dessus de la Figure 1, « Principaux facteurs pouvant influer sur la transition vers le DTG », un schéma en trois colonnes avec des icônes. Les facteurs cliniques et épidémiologiques comprennent le pourcentage de femmes vivant avec le VIH en âge de procréer, l’utilisation de schémas de première intention sous-optimaux, la disponibilité d’options de deuxième et troisième intention et la résistance prétraitement aux INNTI. Les produits comprennent les stocks d’EFV et de DTG, l’accès à la contraception et au test de la charge virale, et la disponibilité d’associations à dose fixe et de formulations génériques. Les facteurs liés aux programmes et aux politiques comprennent l’inclusion dans les lignes directrices nationales, la capacité de la chaîne d’approvisionnement, la formation des prestataires de soins, la traduction de la politique au niveau communautaire, et la surveillance de la toxicité et de l’innocuité pendant la grossesse.",
        "ru": "Изображение страницы с двумя колонками текста над Рисунком 1 «Основные факторы, которые могут влиять на переход на DTG» — схемой из трёх столбцов со значками. Клинические и эпидемиологические факторы включают долю женщин с ВИЧ детородного возраста, использование неоптимальных схем первого ряда, наличие вариантов второго и третьего ряда и претерапевтическую устойчивость к ННИОТ. Товары включают запасы EFV и DTG, доступ к контрацепции и тестированию на вирусную нагрузку, наличие комбинаций с фиксированными дозами и непатентованных форм. Программные и политические факторы включают включение в национальные руководства, потенциал цепочки поставок, обучение медицинских работников, доведение политики до уровня сообществ, мониторинг токсичности и безопасности при беременности."
      },
      "state": "draft"
    },
    {
      "id": "img-p010-1",
      "file": "images/img-p010-1.webp",
      "page": 10,
      "narratives": {
        "en": "A photograph of a woman in a pink dress and a cap sitting on a bed in a room with an orange wall, holding up a small white pill in one hand and a medicine blister pack in the other.",
        "ar": "صورة فوتوغرافية لامرأة ترتدي فستاناً وردياً وقبعة، تجلس على سرير في غرفة ذات جدار برتقالي، وترفع حبة دواء بيضاء صغيرة بإحدى يديها وتمسك بالأخرى شريط أقراص دوائية.",
        "zh": "一张照片：一名身穿粉色连衣裙、头戴帽子的女子坐在一间橙色墙壁房间的床上，一只手举着一粒白色小药片，另一只手拿着药品泡罩包装。",
        "es": "Fotografía de una mujer con vestido rosa y gorra sentada en una cama, en una habitación de pared anaranjada, que sostiene en alto una pequeña píldora blanca con una mano y un blíster de medicamentos con la otra.",
        "fr": "Photographie d’une femme en robe rose et casquette, assise sur un lit dans une pièce au mur orangé, tenant en l’air un petit comprimé blanc d’une main et une plaquette de médicaments de l’autre.",
        "ru": "Фотография женщины в розовом платье и кепке, сидящей на кровати в комнате с оранжевой стеной; в одной руке она держит маленькую белую таблетку, в другой — блистер с лекарствами."
      },
      "state": "draft"
    },
    {
      "id": "img-p013-1",
      "file": "images/img-p013-1.webp",
      "page": 13,
      "narratives": {
        "en": "A photograph of two people with long dark hair standing close together in a doorway of a purple building, behind an open black wrought-iron gate, on a city street.",
        "ar": "صورة فوتوغرافية لشخصين بشعر داكن طويل يقفان متقاربين عند مدخل مبنى بنفسجي، خلف بوابة حديدية سوداء مفتوحة، في شارع بالمدينة.",
        "zh": "一张照片：两名留着深色长发的人紧挨着站在一栋紫色建筑的门口，身处一扇打开的黑色铁艺大门后，位于城市街道旁。",
        "es": "Fotografía de dos personas de pelo largo y oscuro, de pie muy juntas en la entrada de un edificio morado, detrás de una reja negra de hierro forjado abierta, en una calle de ciudad.",
        "fr": "Photographie de deux personnes aux longs cheveux foncés, debout l’une contre l’autre dans l’entrée d’un bâtiment violet, derrière une grille noire en fer forgé ouverte, dans une rue de ville.",
        "ru": "Фотография двух людей с длинными тёмными волосами, стоящих рядом в дверном проёме фиолетового здания за открытыми чёрными коваными воротами на городской улице."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Preferred and alternative first-line ART regimens",
      "pages": [
        7
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "Preferred first-line regimen"
        },
        {
          "titles": "Alternative first-line regimen"
        },
        {
          "titles": "Special circumstances"
        }
      ],
      "rows": [
        [
          "Adults and adolescents",
          "TDF + 3TC (or FTC) + DTGa",
          "TDF + 3TC + EFV 400 mgb",
          "TDF + 3TC (or FTC) + EFV 600 mgb; AZT + 3TC + EFV 600 mgb; TDF + 3TC (or FTC) + PI/rb; TDF + 3TC (or FTC) + RAL; TAFc + 3TC (or FTC) + DTG; ABC + 3TC + DTGa"
        ],
        [
          "Children",
          "ABC + 3TC + DTGd",
          "ABC + 3TC + LPV/r; ABC + 3TC + RALe; TAF + 3TC (or FTC) + DTGf",
          "ABC + 3TC + EFV (or NVP); AZT + 3TC + EFVg (or NVP); AZT + 3TC + LPV/r (or RAL)"
        ],
        [
          "Neonates",
          "AZT + 3TC + RALh",
          "AZT + 3TC + NVP",
          "AZT + 3TC + LPV/ri"
        ]
      ],
      "notes": "3TC: lamivudine; ABC: abacavir; AZT: zidovudine; DTG: dolutegravir; EFV: efavirenz; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; NVP: nevirapine; PI/r: protease inhibitor boosted with ritonavir; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate. aEffective contraception should be offered to adult women and adolescent girls of childbearing age or potential. DTG can be prescribed for adult women and adolescent girls of childbearing age or potential who wish to become pregnant or who are not otherwise using or accessing consistent and effective contraception if they have been fully informed of the potential increase in the risk of neural tube defects (at conception and until the end of the first trimester). If women identify pregnancy after the first trimester, DTG should be initiated or continued for the duration of the pregnancy (Box 2). bEFV-based ART should not be used in settings with national estimates of pretreatment resistance to EFV of 10% or higher. DTG-based ART is preferred, and if DTG is unavailable, a boosted PI-based regimen should be used. The choice of PI/r depends on programmatic characteristics. cTAF may be considered for people with established osteoporosis and/or impaired kidney function. dFor age and weight groups with approved DTG dosing. eRAL should be used as an alternative regimen only if LPV/r solid formulations are not available. fFor age and weight groups with approved TAF dosing. gEFV should not be used for children younger than three years of age. hNeonates starting ART with an RAL-based regimen should transition to an LPV/r solid formulation as soon as possible. iLPV/r syrup or granules can be used if starting after two weeks of age. [Regimens listed on separate lines within one cell are separated here by \"; \". Superscript footnote letters are appended to the drug name, e.g. \"DTGa\", \"TAFc\".]",
      "narratives": {
        "en": "Preferred, alternative and special-circumstance first-line antiretroviral regimens for adults and adolescents, children and neonates, with footnotes on contraception and DTG, EFV pretreatment resistance and age/weight dosing limits.",
        "ar": "نظم العلاج المضاد للفيروسات القهقرية المفضلة والبديلة وتلك الخاصة بالظروف الخاصة في الخط الأول للبالغين والمراهقين والأطفال والولدان، مع حواشٍ بشأن منع الحمل ودولوتيغرافير، ومقاومة إيفافيرنز قبل العلاج، وحدود الجرعات بحسب العمر والوزن.",
        "zh": "成人和青少年、儿童及新生儿的首选、备选和特殊情况下一线抗逆转录病毒治疗方案，脚注涉及避孕与多替拉韦、治疗前依非韦伦耐药以及按年龄/体重给药的限制。",
        "es": "Esquemas antirretrovirales de primera línea preferentes, alternativos y para circunstancias especiales en adultos y adolescentes, niños y recién nacidos, con notas sobre anticoncepción y DTG, resistencia previa al tratamiento a EFV y límites de dosificación por edad y peso.",
        "fr": "Schémas antirétroviraux de première intention privilégiés, de remplacement et pour circonstances particulières chez l’adulte et l’adolescent, l’enfant et le nouveau-né, avec des notes sur la contraception et le DTG, la résistance prétraitement à l’EFV et les limites de posologie selon l’âge et le poids.",
        "ru": "Предпочтительные, альтернативные и применяемые в особых обстоятельствах схемы АРТ первой линии для взрослых и подростков, детей и новорожденных, с примечаниями о контрацепции и DTG, претерапевтической резистентности к EFV и ограничениях дозирования по возрасту и массе тела."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Preferred and alternative second-line ART regimens",
      "pages": [
        8
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "Failing first-line regimen"
        },
        {
          "titles": "Preferred second-line regimen"
        },
        {
          "titles": "Alternative second-line regimens"
        }
      ],
      "rows": [
        [
          "Adults and adolescentsa",
          "TDFb + 3TC (or FTC) + DTGc",
          "AZT + 3TC + ATV/r (or LPV/r)",
          "AZT + 3TC + DRV/rd"
        ],
        [
          "",
          "TDF + 3TC (or FTC) + EFV (or NVP)",
          "AZT + 3TC + DTGc",
          "AZT + 3TC + ATV/r (or LPV/r or DRV/r)d"
        ],
        [
          "",
          "AZT + 3TC + EFV (or NVP)",
          "TDFb + 3TC (or FTC) + DTGc",
          "TDFb + 3TC (or FTC) + ATV/r (or LPV/r or DRV/r)d"
        ],
        [
          "Children and infants",
          "ABC + 3TC + DTGe",
          "AZT+ 3TC + LPV/r (or ATV/rf)",
          "AZT + 3TC + DRV/rg"
        ],
        [
          "",
          "ABC (or AZT) + 3TC + LPV/r",
          "AZT (or ABC) + 3TC + DTGe",
          "AZT (or ABC) + 3TC + RAL"
        ],
        [
          "",
          "ABC (or AZT) + 3TC + EFV",
          "AZT (or ABC) + 3TC + DTGe",
          "AZT (or ABC) + 3TC + LPV/r (or ATV/rf)"
        ],
        [
          "",
          "AZT + 3TC + NVP",
          "ABC + 3TC + DTGe",
          "ABC + 3TC + LPV/r (or ATV/rf or DRV/rg)"
        ]
      ],
      "notes": "3TC: lamivudine; ABC: abacavir; ATV/r: atazanavir/ritonavir; AZT: zidovudine; DRV/r: darunavir/ritonavir; DTG: dolutegravir; EFV: efavirenz; FTC: emtricitabine; LPV/r: lopinavir/ ritonavir; NVP: nevirapine; RAL: raltegravir; TDF: tenofovir disoproxil fumarate. aSequencing if PIs are used in first-line ART: ATV/r (or LPV/r or DRV/r depending on programmatic considerations) + TDF + 3TC (or FTC) and then AZT + 3TC + DTG in second-line ART. bEffective contraception should be offered to adult women and adolescent girls of childbearing age or potential. DTG can be prescribed for adult women and adolescent girls of childbearing age or potential who wish to become pregnant or who are not otherwise using or accessing consistent and effective contraception if they have been fully informed of the potential increase in the risk of neural tube defects (at conception and until the end of the first trimester). If women identify pregnancy after the first trimester, DTG should be initiated or continued for the duration of the pregnancy (Box 2). cTAF (tenofovir alafenamide) can be used as an alternative NRTI in special situations for adults and adolescents. dRAL + LPV/r can be used as an alternative second-line ART regimen for adults and adolescents. eThe European Medicines Agency currently only approves DTG for children weighing at least 15 kg and more widely for children weighing more than 20 kg who can take adult 50- mg film-coated tablets. Studies are ongoing to determine dosing for younger children, with approval expected in early 2020, but the 2016 WHO recommendations for second-line ART still hold (PI-based for children for whom NNRTIs have failed and RAL for children for whom LPV/r has failed). TAF (tenofovir alafenamide) can be used as an alternative NRTI in children weighing at least 25 kg. fATV/r can be used as an alternative to LPV/r for children older than three months, but the limited availability of suitable formulations for children younger than six years, the lack of a fixed-dose formulation and the need for separate administration of the ritonavir booster should be considered when choosing this regimen. gDRV should not be used for children younger than three years and should be combined with appropriate dosing of ritonavir.",
      "narratives": {
        "en": "Preferred and alternative second-line ART regimens according to the failing first-line regimen, for adults and adolescents and for children and infants.",
        "ar": "نظم العلاج المضاد للفيروسات القهقرية المفضلة والبديلة في الخط الثاني بحسب نظام الخط الأول الذي فشل، للبالغين والمراهقين وللأطفال والرضع.",
        "zh": "根据失败的一线方案，列出成人和青少年以及儿童和婴儿的首选和备选二线抗逆转录病毒治疗方案。",
        "es": "Esquemas antirretrovirales de segunda línea preferentes y alternativos según el esquema de primera línea que ha fracasado, para adultos y adolescentes y para niños y lactantes.",
        "fr": "Schémas antirétroviraux de deuxième intention privilégiés et de remplacement selon le schéma de première intention en échec, chez l’adulte et l’adolescent et chez l’enfant et le nourrisson.",
        "ru": "Предпочтительные и альтернативные схемы АРТ второй линии в зависимости от неэффективной схемы первой линии для взрослых и подростков, а также для детей и младенцев."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Considerations for transition to TDF + 3TC + DTG among adults and adolescents",
      "pages": [
        11
      ],
      "columns": [
        {
          "titles": "Treatment transition scenario"
        },
        {
          "titles": "Preferred approach"
        },
        {
          "titles": "Comments"
        }
      ],
      "rows": [
        [
          "DTG for people living with HIV initiating ART",
          "",
          ""
        ],
        [
          "Adults and adolescentsa",
          "Initiate TDF + 3TC + DTG",
          "• Potential risk of neural tube defects among infants exposed to DTG during the conception period • Women not using or accessing contraception or who want to be pregnant can use DTG or EFV based on informed choice of the risks and benefits of each regimen"
        ],
        [
          "Pregnant and breastfeeding womenb",
          "Initiate TDF + 3TC + DTG",
          "• Possibility of conception during breastfeeding remains"
        ],
        [
          "TB coinfection",
          "Initiate TDF + 3TC + DTG (DTG dose adjustment needed)",
          "• DTG 50 mg twice daily if rifampicin is being used as the anti-TB regimen"
        ],
        [
          "DTG for people living with HIV already using a first-line ART regimen",
          "",
          ""
        ],
        [
          "Clinical or immune failure or viral load not suppressed",
          "Switch to AZT + 3TC + DTG or PI/rc",
          "• No evidence to support the efficacy of DTG when used in combination with an inactive NRTI backbone • Provide adherence support"
        ],
        [
          "Viral load suppressed",
          "Substitution to TDF + 3TC + DTG may be considered according to national recommendations",
          "• Substitution should be considered in the context of drug supply and patient choice • Substitution may confer new side-effects and interfere with adherence • DTG regimens may be more durable in the long term"
        ],
        [
          "Clinically and immunologically stabled and viral load unknown",
          "Give priority to viral load testing or consider other programmatic or clinical indications indications for substitution to DTG based ART",
          "• No evidence to support the efficacy of DTG when used in combination with an inactive NRTI backbone • provide adherence support"
        ],
        [
          "Stabled on suboptimal first-line ART regimens",
          "Substitute to TDF + 3TC + DTG",
          "• Substitution may confer new side-effects. • Provide adherence support"
        ]
      ],
      "notes": "3TC: lamivudine; AZT: zidovudine; DTG: dolutegravir; EFV: efavirenz; NRTI: nucleoside reverse-transcriptase inhibitor; PI/r: protease inhibitor boosted with ritonavir; TDF: tenofovir disoproxil fumarate; TB: tuberculosis. aEffective contraception should be offered to adult women and adolescent girls of childbearing age or potential. DTG can be prescribed for adult women and adolescent girls of childbearing age or potential who wish to become pregnant or who are not otherwise using or accessing consistent and effective contraception if they have been fully informed of the potential increase in the risk of neural tube defects (at conception and until the end of the first trimester). bIf women identify pregnancy after the first trimester, DTG should be initiated or continued for the duration of the pregnancy. cAfter adherence check and persistent detectable viral load. dDefined as stable based on national guidelines.",
      "narratives": {
        "en": "Preferred approaches and comments for moving adults and adolescents to TDF + 3TC + DTG, for people initiating ART (general, pregnant and breastfeeding women, TB coinfection) and for people already on first-line ART (by viral load, clinical status and regimen).",
        "ar": "النُهُج المفضلة والتعليقات بشأن نقل البالغين والمراهقين إلى نظام TDF + 3TC + DTG، لمن يبدؤون العلاج المضاد للفيروسات القهقرية (عموماً، والحوامل والمرضعات، والمصابون بعدوى مصاحبة بالسل) ولمن يتلقون بالفعل علاج الخط الأول (بحسب الحمل الفيروسي والحالة السريرية والنظام العلاجي).",
        "zh": "关于将成人和青少年过渡到TDF + 3TC + DTG方案的首选做法和说明，分为开始抗逆转录病毒治疗者（一般人群、孕妇和哺乳期妇女、合并结核感染者）和已接受一线治疗者（按病毒载量、临床状况和方案）。",
        "es": "Enfoques preferentes y observaciones para la transición de adultos y adolescentes a TDF + 3TC + DTG, para quienes inician el TAR (en general, embarazadas y mujeres lactantes, coinfección por tuberculosis) y para quienes ya reciben TAR de primera línea (según carga viral, situación clínica y esquema).",
        "fr": "Approches privilégiées et commentaires pour la transition des adultes et adolescents vers TDF + 3TC + DTG, pour les personnes qui commencent un TAR (en général, femmes enceintes et allaitantes, co-infection tuberculeuse) et pour celles déjà sous TAR de première intention (selon la charge virale, l’état clinique et le schéma).",
        "ru": "Предпочтительные подходы и комментарии по переводу взрослых и подростков на схему TDF + 3TC + DTG для лиц, начинающих АРТ (в целом, беременные и кормящие женщины, коинфекция ТБ), и для лиц, уже получающих АРТ первой линии (в зависимости от вирусной нагрузки, клинического состояния и схемы)."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. Considerations for transition to optimal ART regimens for children who are considered stable on ART based on national guidelines",
      "pages": [
        12
      ],
      "columns": [
        {
          "titles": "Current regimen"
        },
        {
          "titles": "Weight"
        },
        {
          "titles": "Optimal regimen for transition"
        },
        {
          "titles": "Considerations"
        }
      ],
      "rows": [
        [
          "AZT + 3TC + NVP; AZT + 3TC + EFV; ABC + 3TC + NVP",
          "<20 kg",
          "ABC + 3TC + LPV/r",
          "If stable, children can be transitioned to DTG when they reach 20 kg"
        ],
        [
          "",
          "20–30kg",
          "ABC + 3TC + DTG",
          "If stable, children can be transitioned to TDF + 3TC + DTG when they reach 30 kg"
        ],
        [
          "",
          "> 30 kg",
          "TDF + 3TC + DTG",
          "–"
        ],
        [
          "ABC + 3TC + EFV",
          "<20 kg",
          "No change until they reach 20 kg unless treatment failure occurs",
          "Transition to optimal regimens for these children is of value once they reach 20 kg and DTG can be used maintaining once-daily administration"
        ],
        [
          "",
          "20–30 kg",
          "ABC + 3TC + DTG",
          "If stable, children can be transitioned to TDF + 3TC + DTG when they reach 30 kg"
        ],
        [
          "",
          "> 30 kg",
          "TDF + 3TC + DTG",
          "–"
        ],
        [
          "ABC + 3TC + LPV/r; AZT + 3TC + LPV/r",
          "<20 kg",
          "No change until they reach 20 kg unless treatment failure occurs",
          "Ensure the use of tablets as soon as possible to reduce pill burden. Transition from AZT + 3TC + LPV/r to ABC + 3TC + LPV/r can also be considered to reduce the pill burden and preserve the antiviral advantage of NRTI’s sequencing"
        ],
        [
          "",
          "20–30kg",
          "ABC + 3TC + DTG",
          "If stable, children can be transitioned to TDF + 3TC + DTG when they reach 30 kg"
        ],
        [
          "",
          "> 30kg",
          "TDF + 3TC + DTG",
          "–"
        ]
      ],
      "notes": "3TC: lamivudine; ABC: abacavir; AZT: zidovudine; DTG: dolutegravir; EFV: efavirenz; LPV/r: lopinavir/ritonavir; NRTI: nucleoside reverse-transcriptase inhibitor; NVP: nevirapine; TDF: tenofovir disoproxil fumarate. [Regimens listed on separate lines in the \"Current regimen\" cell are separated here by \"; \".]",
      "narratives": {
        "en": "For children considered stable on ART, the table gives, by current regimen and weight band (<20 kg, 20–30 kg, >30 kg), the optimal regimen to transition to and related considerations.",
        "ar": "يعرض الجدول، للأطفال الذين يُعتبرون مستقرين على العلاج المضاد للفيروسات القهقرية، النظام الأمثل الذي ينبغي الانتقال إليه والاعتبارات ذات الصلة، بحسب النظام الحالي وفئة الوزن (أقل من 20 كغ، و20–30 كغ، وأكثر من 30 كغ).",
        "zh": "该表针对被认为抗逆转录病毒治疗稳定的儿童，按当前方案和体重段（<20公斤、20–30公斤、>30公斤）列出应过渡到的最佳方案及相关考虑。",
        "es": "Para los niños considerados estables con TAR, el cuadro indica, según el esquema actual y la franja de peso (<20 kg, 20-30 kg, >30 kg), el esquema óptimo al que realizar la transición y las consideraciones correspondientes.",
        "fr": "Pour les enfants considérés comme stables sous TAR, le tableau indique, selon le schéma actuel et la tranche de poids (<20 kg, 20-30 kg, >30 kg), le schéma optimal vers lequel effectuer la transition et les considérations correspondantes.",
        "ru": "Для детей, считающихся стабильными на АРТ, в таблице указаны в зависимости от текущей схемы и весовой категории (<20 кг, 20–30 кг, >30 кг) оптимальная схема для перехода и соответствующие соображения."
      },
      "csv": "tables/table-4.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 16,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 17,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 6
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 4
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p14); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 14,
      "note": "14 of 17 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-325892"
  }
}
